Q4 Earnings Estimate for Insulet Issued By Leerink Partnrs

Insulet Co. (NASDAQ:PODD - Free Report) - Leerink Partnrs reduced their Q4 2024 earnings per share estimates for Insulet in a research note issued on Monday, November 25th. Leerink Partnrs analyst M. Kratky now expects that the medical instruments supplier will post earnings of $0.97 per share for the quarter, down from their prior estimate of $0.99. The consensus estimate for Insulet's current full-year earnings is $3.22 per share. Leerink Partnrs also issued estimates for Insulet's Q2 2025 earnings at $0.87 EPS, Q3 2025 earnings at $1.14 EPS, Q4 2025 earnings at $1.20 EPS, FY2025 earnings at $3.89 EPS, FY2026 earnings at $5.21 EPS and FY2027 earnings at $6.49 EPS.

Several other research analysts also recently issued reports on PODD. Citigroup boosted their price objective on shares of Insulet from $250.00 to $275.00 and gave the stock a "buy" rating in a report on Tuesday, October 1st. Piper Sandler increased their price objective on shares of Insulet from $230.00 to $285.00 and gave the company an "overweight" rating in a report on Tuesday, September 17th. BTIG Research lifted their target price on shares of Insulet from $260.00 to $270.00 and gave the stock a "buy" rating in a report on Friday, November 8th. Raymond James lifted their target price on Insulet from $213.00 to $260.00 and gave the stock an "outperform" rating in a report on Monday, October 14th. Finally, Sanford C. Bernstein initiated coverage on Insulet in a report on Wednesday, November 6th. They issued an "outperform" rating and a $300.00 price target for the company. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $253.27.

Insulet Stock Performance

Shares of PODD stock traded down $0.16 during trading on Tuesday, reaching $266.42. The company had a trading volume of 522,170 shares, compared to its average volume of 773,877. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet has a one year low of $160.19 and a one year high of $279.40. The firm's 50 day simple moving average is $241.97 and its two-hundred day simple moving average is $211.65. The company has a market capitalization of $18.69 billion, a PE ratio of 45.62, a PEG ratio of 4.02 and a beta of 1.22.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Blue Trust Inc. lifted its holdings in Insulet by 84.1% during the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock worth $30,000 after buying an additional 58 shares during the period. International Assets Investment Management LLC bought a new position in Insulet in the 2nd quarter valued at $32,000. Venturi Wealth Management LLC increased its stake in shares of Insulet by 633.3% during the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier's stock worth $36,000 after purchasing an additional 133 shares during the last quarter. UMB Bank n.a. grew its stake in shares of Insulet by 81.0% during the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier's stock worth $37,000 after acquiring an additional 81 shares during the period. Finally, CVA Family Office LLC increased its stake in shares of Insulet by 138.1% in the second quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier's stock worth $50,000 after purchasing an additional 145 shares in the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.